NCI Backs Senticell's Red Blood Cell Liquid Biopsy for Early-Stage Lung Cancer

Senticell, a biotechnology company, has been awarded a Small Business Technology Transfer (STTR) grant from the National Cancer Institute to advance an RBC-based liquid biopsy aimed at early-stage lung cancer.

The award is non-dilutive federal funding, meaning it does not come with the equity cost of a venture round. Its stated purpose is to support preclinical and clinical work validating red blood cell-bound tumor DNA as an early detection biomarker for non-small cell lung cancer (NSCLC).

The technical premise is a departure from the circulating tumor DNA approaches that have dominated the liquid biopsy field. Most commercial and investigational blood tests for cancer look for fragments of tumor DNA floating free in plasma. Senticell's program instead focuses on tumor DNA that associates with red blood cells, and it is that bound fraction the company intends to validate as a signal capable of flagging disease at an earlier stage.

Early detection is the hardest and most commercially valuable problem in lung cancer diagnostics. NSCLC is typically diagnosed after symptoms appear, when the disease is often advanced and treatment options narrow. A blood-based test that reliably detects the cancer while it is still localized would address a large unmet need, though demonstrating that kind of sensitivity and specificity in a clinical study is a demanding bar.

STTR grants are structured to move academic-origin science toward commercialization, requiring a partnership between a small business and a nonprofit research institution. That structure fits a program that still sits at the biomarker validation stage, where the near-term milestones are analytical and clinical evidence rather than product launch.

The grant gives Senticell a route to fund that validation work without selling equity, an increasingly attractive option for diagnostics developers facing a constrained venture market for early-stage life sciences. Whether the red blood cell-bound DNA signal holds up in patient samples will determine how far the program travels from grant-funded research toward a test that clinicians can order.